CXCR2 and thyroid gland carcinoma: More recently, Liotti et al. provided evidence that reparixin (an inhibitor of the CXCL8 receptors, CXCR1, and CXCR2) reduces cell survival, proliferation, EMT, and stemness of several thyroid cancer cell lines (147).